These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Phillips AN; Pillay D; Miners AH; Bennett DE; Gilks CF; Lundgren JD Lancet; 2008 Apr; 371(9622):1443-51. PubMed ID: 18440426 [TBL] [Abstract][Full Text] [Related]
3. A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries. Colebunders R; Moses KR; Laurence J; Shihab HM; Semitala F; Lutwama F; Bakeera-Kitaka S; Lynen L; Spacek L; Reynolds SJ; Quinn TC; Viner B; Mayanja-Kizza H Lancet Infect Dis; 2006 Jan; 6(1):53-9. PubMed ID: 16377535 [TBL] [Abstract][Full Text] [Related]
4. Antiretroviral treatment in resource-poor settings: clinical research priorities. Rabkin M; El-Sadr W; Katzenstein DA; Mukherjee J; Masur H; Mugyenyi P; Munderi P; Darbyshire J Lancet; 2002 Nov; 360(9344):1503-5. PubMed ID: 12433534 [No Abstract] [Full Text] [Related]
5. Challenges in implementing HIV laboratory monitoring in resource-constrained settings: how to do more with less. Bélec L; Bonn JP Future Microbiol; 2011 Nov; 6(11):1251-60. PubMed ID: 22082287 [TBL] [Abstract][Full Text] [Related]
6. Report from the Tenth Retrovirus Conference. Clinical trials in resource-poor settings. Friedland G AIDS Clin Care; 2003 Apr; 15(4):31-2. PubMed ID: 12712944 [No Abstract] [Full Text] [Related]
7. Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching. Elliott JH; Lynen L; Calmy A; De Luca A; Shafer RW; Zolfo M; Clotet B; Huffam S; Boucher CA; Cooper DA; Schapiro JM AIDS; 2008 Oct; 22(16):2053-67. PubMed ID: 18753937 [No Abstract] [Full Text] [Related]
8. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis. Boyer S; March L; Kouanfack C; Laborde-Balen G; Marino P; Aghokeng AF; Mpoudi-Ngole E; Koulla-Shiro S; Delaporte E; Carrieri MP; Spire B; Laurent C; Moatti JP; Lancet Infect Dis; 2013 Jul; 13(7):577-86. PubMed ID: 23602084 [TBL] [Abstract][Full Text] [Related]
9. Developments in CD4 and viral load monitoring in resource-limited settings. Rowley CF Clin Infect Dis; 2014 Feb; 58(3):407-12. PubMed ID: 24218101 [TBL] [Abstract][Full Text] [Related]
10. Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies. Ouattara EN; Robine M; Eholié SP; MacLean RL; Moh R; Losina E; Gabillard D; Paltiel AD; Danel C; Walensky RP; Anglaret X; Freedberg KA Clin Infect Dis; 2016 Jun; 62(11):1454-1462. PubMed ID: 26936666 [TBL] [Abstract][Full Text] [Related]
11. Clinical impact and cost of laboratory monitoring need review even in resource-rich setting. Sayana S; Javanbakht M; Weinstein M; Khanlou H J Acquir Immune Defic Syndr; 2011 Mar; 56(3):e97-8. PubMed ID: 21317583 [No Abstract] [Full Text] [Related]
12. Suitable monitoring approaches to antiretroviral therapy in resource-poor settings: setting the research agenda. Kent DM; McGrath D; Ioannidis JP; Bennish ML Clin Infect Dis; 2003 Jul; 37(Suppl 1):S13-24. PubMed ID: 12822128 [TBL] [Abstract][Full Text] [Related]
13. Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings? Bagchi S; Kempf MC; Westfall AO; Maherya A; Willig J; Saag MS Clin Infect Dis; 2007 Jan; 44(1):135-8. PubMed ID: 17143829 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Ivers LC; Kendrick D; Doucette K Clin Infect Dis; 2005 Jul; 41(2):217-24. PubMed ID: 15983918 [TBL] [Abstract][Full Text] [Related]
15. Clinical impact and cost of monitoring for asymptomatic laboratory abnormalities among patients receiving antiretroviral therapy in a resource-poor setting. Koenig SP; Schackman BR; Riviere C; Leger P; Charles M; Severe P; Lastimoso C; Colucci N; Pape JW; Fitzgerald DW Clin Infect Dis; 2010 Sep; 51(5):600-8. PubMed ID: 20649436 [TBL] [Abstract][Full Text] [Related]
16. The DART trial: 'The doctor's dilemma' revisited. Nunes EP; Grinsztejn B; Schechter M J Antimicrob Chemother; 2011 May; 66(5):964-7. PubMed ID: 21393146 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis. Hamers RL; Sawyer AW; Tuohy M; Stevens WS; Rinke de Wit TF; Hill AM; AIDS; 2012 Aug; 26(13):1663-72. PubMed ID: 22695297 [TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of monitoring virologic responses to antiretroviral therapy in HIV-infected children in resource-limited settings. Schneider K; Puthanakit T; Kerr S; Law MG; Cooper DA; Donovan B; Phanuphak N; Sirisanthana V; Ananworanich J; Ohata J; Wilson DP AIDS; 2011 Jun; 25(9):1143-51. PubMed ID: 21505319 [TBL] [Abstract][Full Text] [Related]
19. Monitoring of antiretroviral therapy in low-resource settings. Walensky RP; Freedberg KA; Weinstein MC Lancet; 2008 Jul; 372(9635):288; author reply 289. PubMed ID: 18657699 [No Abstract] [Full Text] [Related]
20. Community-based approaches to HIV treatment in resource-poor settings. Farmer P; Léandre F; Mukherjee JS; Claude M; Nevil P; Smith-Fawzi MC; Koenig SP; Castro A; Becerra MC; Sachs J; Attaran A; Kim JY Lancet; 2001 Aug; 358(9279):404-9. PubMed ID: 11502340 [No Abstract] [Full Text] [Related] [Next] [New Search]